Geode Capital Management LLC Acquires 284,047 Shares of FibroBiologics, Inc. (NASDAQ:FBLG)

Geode Capital Management LLC increased its holdings in shares of FibroBiologics, Inc. (NASDAQ:FBLG) by 90.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 599,760 shares of the company’s stock after purchasing an additional 284,047 shares during the quarter. Geode Capital Management LLC’s holdings in FibroBiologics were worth $1,854,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of FBLG. Fund Evaluation Group LLC purchased a new position in FibroBiologics in the 2nd quarter worth about $5,265,000. State Street Corp grew its stake in shares of FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after acquiring an additional 99,789 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of FibroBiologics by 5.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock valued at $215,000 after purchasing an additional 3,451 shares during the last quarter. Bank of New York Mellon Corp bought a new position in FibroBiologics during the second quarter valued at approximately $342,000. Finally, Barclays PLC lifted its position in FibroBiologics by 363.2% during the third quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after purchasing an additional 31,331 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on FBLG shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of FibroBiologics in a research report on Wednesday, November 13th. Maxim Group assumed coverage on FibroBiologics in a report on Tuesday, September 24th. They issued a “buy” rating and a $12.00 target price on the stock. Rodman & Renshaw began coverage on FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price target for the company. Finally, D. Boral Capital reiterated a “buy” rating and issued a $16.00 price objective on shares of FibroBiologics in a research note on Friday, December 27th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, FibroBiologics has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Trading Down 8.8 %

NASDAQ FBLG opened at $2.06 on Thursday. FibroBiologics, Inc. has a fifty-two week low of $1.08 and a fifty-two week high of $55.00. The business’s fifty day moving average is $2.54 and its 200 day moving average is $3.02.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.